Liver transplantation in metastatic colorectal cancer

Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected pop...

Descripción completa

Detalles Bibliográficos
Autores: Ros-Montañá, Francisco Javier|||0000-0002-8137-5415, Salvà, Francesc|||0000-0001-9240-4907, Dopazo, Cristina|||0000-0001-6274-5911, López, Daniel, Saoudi, Nadia, Baraibar, Iosune|||0000-0002-3500-9641, Charco, Ramon|||0000-0001-9709-6288, Tabernero, Josep|||0000-0002-2495-8139, Elez, Elena|||0000-0002-4653-6324
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:281642
Acceso en línea:https://ddd.uab.cat/record/281642
https://dx.doi.org/urn:doi:10.1038/s41416-023-02213-1
Access Level:acceso abierto
Palabra clave:Colorectal cancer
Surgical oncology
Descripción
Sumario:Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected population can improve clinical outcomes with an impressive 5-year overall survival of 83%. Despite liver transplantation appearing to be a promising therapeutical option for well-selected patients with mCRC with the liver-limited disease, these data come from small monocentric trials which included a heterogeneous population. Currently, several clinical trials are evaluating liver transplantation in this scenario, aiming for a more accurate patient selection by integrating liquid biopsy, tissue profiling, and nuclear medicine to the already known clinical biomarkers that eventually may lead to a survival improvement. In this paper, the clinical outcomes and inclusion criteria from the most relevant clinical trials and clinical series involving liver transplantation in patients with liver-limited disease colorectal cancer are reviewed as well as the trials currently recruiting.